[go: up one dir, main page]

ZA201500040B - Methods of reducing the risk of a cardiovascular event in a subject on statin therapy - Google Patents

Methods of reducing the risk of a cardiovascular event in a subject on statin therapy

Info

Publication number
ZA201500040B
ZA201500040B ZA2015/00040A ZA201500040A ZA201500040B ZA 201500040 B ZA201500040 B ZA 201500040B ZA 2015/00040 A ZA2015/00040 A ZA 2015/00040A ZA 201500040 A ZA201500040 A ZA 201500040A ZA 201500040 B ZA201500040 B ZA 201500040B
Authority
ZA
South Africa
Prior art keywords
risk
subject
reducing
methods
cardiovascular event
Prior art date
Application number
ZA2015/00040A
Other languages
English (en)
Inventor
Soni Paresh
Original Assignee
Southern Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49784037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201500040(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Southern Co filed Critical Southern Co
Publication of ZA201500040B publication Critical patent/ZA201500040B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
ZA2015/00040A 2012-06-29 2015-01-06 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy ZA201500040B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666447P 2012-06-29 2012-06-29
PCT/US2013/048559 WO2014005013A2 (fr) 2012-06-29 2013-06-28 Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine

Publications (1)

Publication Number Publication Date
ZA201500040B true ZA201500040B (en) 2016-03-30

Family

ID=49784037

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00040A ZA201500040B (en) 2012-06-29 2015-01-06 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy

Country Status (42)

Country Link
US (26) US9603826B2 (fr)
EP (5) EP2866801A4 (fr)
JP (3) JP2015522029A (fr)
KR (1) KR20150036252A (fr)
CN (4) CN104582698A (fr)
AU (3) AU2013282394B2 (fr)
BR (1) BR112014032905B1 (fr)
CA (3) CA3067008C (fr)
CL (1) CL2014003534A1 (fr)
CO (1) CO7190236A2 (fr)
CR (1) CR20140591A (fr)
CU (1) CU20140151A7 (fr)
CY (1) CY1123749T1 (fr)
DK (2) DK3363433T3 (fr)
DO (1) DOP2014000301A (fr)
EA (2) EA039108B1 (fr)
EC (1) ECSP15002815A (fr)
ES (2) ES2993235T3 (fr)
FI (1) FI3815684T3 (fr)
GE (1) GEP201706768B (fr)
HK (1) HK1204271A1 (fr)
HR (1) HRP20210309T1 (fr)
HU (2) HUE069516T2 (fr)
IL (3) IL313596A (fr)
LT (2) LT3363433T (fr)
MA (1) MA50258B2 (fr)
MX (6) MX378496B (fr)
MY (1) MY187464A (fr)
NI (1) NI201400155A (fr)
NZ (5) NZ703267A (fr)
PE (1) PE20150770A1 (fr)
PH (1) PH12014502849A1 (fr)
PL (2) PL3363433T3 (fr)
PT (2) PT3363433T (fr)
RS (2) RS65970B1 (fr)
SG (5) SG10201913647QA (fr)
SI (2) SI3815684T1 (fr)
SM (2) SMT202400504T1 (fr)
TN (1) TN2014000540A1 (fr)
UA (2) UA118015C2 (fr)
WO (1) WO2014005013A2 (fr)
ZA (1) ZA201500040B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
NZ595852A (en) 2009-04-29 2014-07-25 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
WO2010127099A2 (fr) 2009-04-29 2010-11-04 Amarin Corporation Plc Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
SMT202100223T1 (it) 2009-06-15 2021-05-07 Amarin Pharmaceuticals Ie Ltd Composizioni e metodi per abbassare i trigliceridi senza aumentare i livelli di ldl-c in un soggetto in terapia concomitante con statine
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
EP2646013A4 (fr) 2010-11-29 2014-03-26 Amarin Pharma Inc Composition à faible éructation et méthodes de traitement et/ou de prévention de maladie cardiovasculaire chez un sujet présentant une allergie/hypersensibilité aux poissons
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
NZ703267A (en) 2012-06-29 2017-01-27 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3762026A1 (fr) * 2018-03-06 2021-01-13 Sanofi Biotechnology Utilisation d'un inhibiteur de pcsk9 pour réduire le risque cardiovasculaire
TN2021000028A1 (en) * 2018-08-17 2022-10-03 Amarin Pharmaceuticals Ie Ltd Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
CN113332269A (zh) * 2018-09-24 2021-09-03 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
PL4056176T3 (pl) * 2018-09-24 2024-08-26 Amarin Pharmaceuticals Ireland Limited Sposoby zmniejszania ryzyka zdarzeń krążeniowo-naczyniowych u osobnika
US10813612B2 (en) 2019-01-25 2020-10-27 Cleerly, Inc. Systems and method of characterizing high risk plaques
KR20220122616A (ko) * 2019-11-12 2022-09-02 애머린 파마슈티칼스 아일랜드 리미티드 심방 세동 및/또는 심방 조동을 갖는 대상체에서 심혈관 사건의 위험을 감소시키는 방법
CN114761347B (zh) * 2019-12-05 2024-08-13 因温特奥股份公司 用于构建自动扶梯或移动人行道的承载结构的方法
US11969280B2 (en) 2020-01-07 2024-04-30 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US11501436B2 (en) 2020-01-07 2022-11-15 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US20220392065A1 (en) 2020-01-07 2022-12-08 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
WO2022212655A1 (fr) * 2021-03-31 2022-10-06 Amarin Pharmaceuticals Ireland Limited Compositions comprenant de l'epa et de la colchicine et leurs procédés d'utilisation pour réduire le risque d'accidents cardiovasculaires chez un sujet
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법
US12144669B2 (en) 2022-03-10 2024-11-19 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US20230289963A1 (en) 2022-03-10 2023-09-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
KR20230143081A (ko) 2022-04-04 2023-10-11 삼성전자주식회사 중성지방 측정 장치 및 방법

Family Cites Families (320)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
JPS57112593A (en) 1980-12-26 1982-07-13 Koken Boring Machine Co Lathe drill
US4377526A (en) 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
CA1239587A (fr) 1983-10-24 1988-07-26 David Rubin Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins
US4526902A (en) 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
JPS6135356A (ja) 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
EP0347509A1 (fr) 1988-06-21 1989-12-27 Century Laboratories Inc. Procédé d'extraction et purification d'acides gras polyinsaturés à partir de sources naturelles
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
CA1321767C (fr) 1986-12-26 1993-08-31 Noriko Okazaki Procede pour la production d'acide eicosapentaenoique
JPS63185390A (ja) 1987-01-27 1988-07-30 Suntory Ltd 藻類によるエイコサペンタエン酸の製造方法
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5116871A (en) 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
US5457130A (en) 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CA2043615C (fr) 1990-06-04 2001-08-14 Kazuhiko Hata Methode de preparation de l'acide icosapentenoique ou d'un ester de ce dernier
GB9012651D0 (en) 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
WO1993003450A1 (fr) 1991-07-30 1993-02-18 North Carolina State University Procede et appareil pour mesurer les taux sanguins de lipoproteines par spectroscopie rmn
DE4133694C2 (de) 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
JPH0692847A (ja) 1992-09-11 1994-04-05 Mochida Pharmaceut Co Ltd 骨粗鬆症治療剤
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9318611D0 (en) 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JP3325995B2 (ja) 1994-02-28 2002-09-17 ミサワホーム株式会社 パネル接合構造
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JP3368100B2 (ja) 1994-06-02 2003-01-20 キヤノン株式会社 静電荷像現像用トナー
AU711482B2 (en) 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
JP2780154B2 (ja) 1995-02-17 1998-07-30 株式会社ヤクルト本社 ヨーグルト
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH0959206A (ja) 1995-08-25 1997-03-04 Nippon Oil & Fats Co Ltd エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
GB9519661D0 (en) 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
WO1997039759A2 (fr) 1996-04-24 1997-10-30 Brigham And Women's Hospital Acides gras omega 3 et phosphatidylcholine omega 3 utilises dans le traitement de troubles bipolaires
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6248398B1 (en) 1996-05-22 2001-06-19 Applied Materials, Inc. Coater having a controllable pressurized process chamber for semiconductor processing
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
DK0956013T3 (da) 1996-10-11 2003-08-04 Scarista Ltd Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
EP0843972B1 (fr) 1996-11-20 2002-07-31 N.V. Nutricia Composition nutritionnelle comprenant des corps gras pour le traitement du syndrome métabolique
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
EP1025842B1 (fr) 1997-10-30 2004-07-21 Morishita Jintan Co., Ltd. Capsule a double couche d'un acide gras insature ou un derive de celui-ci, et procede de fabrication
IL135154A (en) 1997-11-25 2005-05-17 Warner Lambert Co Inhbition of lipoprotein oxidation
EP1039893B1 (fr) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Compositions pharmaceutiques contenant une huile d'acide gras omega-3
NZ500703A (en) 1998-11-04 2001-06-29 F Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CA2260397A1 (fr) 1999-01-29 2000-07-29 Atlantis Marine Inc. Methode pour convertir l'huile fondue de triglyceride provenant de sources marines en huile alimentaire douce et stable
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
DE60005152T2 (de) 1999-03-03 2004-07-08 Eurovita A/S Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer
DK1166652T4 (en) 1999-03-04 2016-10-24 Suntory Holdings Ltd The use of material containing 4, 7, 10, 13, 16-docosapentaenoic acid
US20020054871A1 (en) 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2001025519A (ja) 1999-05-11 2001-01-30 Mamiya Op Co Ltd ゴルフクラブ用シャフト
US7112609B2 (en) 1999-06-01 2006-09-26 Drugtech Corporation Nutritional supplements
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2311974A1 (fr) 1999-06-28 2000-12-28 Nisshin Flour Milling Co., Ltd. Procedes pour la separation selective et la purification des acides eicosapentanoique et docosahexanoique et de leurs esters
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
PT1072198E (pt) 1999-07-28 2008-06-17 Swiss Caps Rechte & Lizenzen Preparado, especialmente para utilização como medicamento e/ou como suplemento alimentar
WO2001015552A1 (fr) 1999-08-30 2001-03-08 Ocean Nutrition Canada Ltd. Supplement nutritionnel destine a abaisser le taux de cholesterol et de triglycerides seriques
JP4170542B2 (ja) 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
EP1125914A1 (fr) 2000-02-14 2001-08-22 Nisshin Flour Milling Co., Ltd. Procédé de séparation et de purification d'acide eicosapentaénoique ou d'un ester de celui-ci
DK1157692T3 (da) 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
GB0016452D0 (en) 2000-07-04 2000-08-23 Kilgowan Limited Vitamin K and essential fatty acids
JP4391673B2 (ja) 2000-08-08 2009-12-24 花王株式会社 油脂組成物
CA2419406A1 (fr) 2000-08-15 2002-02-21 Pfizer Products Inc. Combinaisons pharmaceutiques de torcetrapib et d'atorvastatine ou de derives hydroxyles pour le traitement de l'atherosclerose, de l'angine et des faibles niveaux de lipoproteinesde haute densite
GB0101198D0 (en) 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
IL159038A0 (en) 2001-05-30 2004-05-12 Laxdale Ltd Coenzyme q and eicosapentaenoic acid (epa)
US20120214771A1 (en) 2001-07-27 2012-08-23 Fontini Sampalis Compositions for treatment of cardiometabolic disorders
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030144219A1 (en) 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
JP2003306690A (ja) 2002-02-18 2003-10-31 Nooburu:Kk 多価不飽和脂肪酸含有油脂組成物
US20030166614A1 (en) 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2485116C (fr) 2002-05-03 2013-02-05 Pronova Biocare As Utilisation d'acide eicosapentanoique (epa) et d'acide docosahexanoique (dha) aux fins d'une prevention secondaire de manifestations neurologiques, de l'ictus notamment
NZ537022A (en) 2002-06-05 2006-10-27 Ivax Pharmaceuticals S Reduction of gelatin cross-linking in the gelatin shell of gelatin capsules by incorporating a free amino acid into the capsule shall and a carboxylic acid ester into the capsule filling
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20040001874A1 (en) 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
JP2005532394A (ja) 2002-07-02 2005-10-27 ガリレオ ファーマシューティカルズ， インコーポレイティド 雌性被験体における炎症性症状および／またはバイオマーカーの低減のための組成物および方法
US20060211761A1 (en) 2002-07-08 2006-09-21 Yatendra Kumar Hmg-coa-reductase inhibitors
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
AU2003257550A1 (en) 2002-08-20 2004-03-11 Nikken Chemicals Co., Ltd. Soft capsule preparation
DE20214847U1 (de) 2002-09-24 2004-02-19 Voss Automotive Gmbh Anschlußvorrichtung für Rohrleitungen
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004048496A1 (fr) 2002-11-22 2004-06-10 Nippon Suisan Kaisha, Ltd. Composition contenant une substance organique ayant une liaison double a stabilite d'oxydation amelioree
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
GB0301701D0 (en) 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
CN1816287A (zh) 2003-01-31 2006-08-09 宝洁公司 改善哺乳动物角质组织外观的方法
CA2515293C (fr) 2003-02-07 2012-03-20 Mochida Pharmaceutical Co., Ltd. Acide eicosapentaenoique utilise pour ameliorer le pronostic dans le traitement de l'hemorragie sous sous-arachnoidienne
JP4570563B2 (ja) 2003-02-21 2010-10-27 持田製薬株式会社 リバビリン／インターフェロン併用療法の副作用軽減剤
EP1603551A2 (fr) 2003-03-05 2005-12-14 Solvay Pharmaceuticals GmbH Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques
CA2516142A1 (fr) 2003-03-18 2004-09-30 Novartis Ag Compositions comprenant des acides gras et des acides amines
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US6846942B2 (en) 2003-05-20 2005-01-25 David Rubin Method for preparing pure EPA and pure DHA
US7205329B2 (en) 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
EP1637134A4 (fr) 2003-06-20 2010-01-27 Mochida Pharm Co Ltd Composition pour la prevention et le traitement des varices
WO2005020785A2 (fr) 2003-07-15 2005-03-10 The Regents Of The University Of California Decouverte du micro-organisme provoquant la maladie auto-immune humaine appelee cirrhose biliaire primaire
AU2003249492A1 (en) 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
WO2005047479A2 (fr) 2003-11-12 2005-05-26 E.I. Dupont De Nemours And Company $g(d)-15 desaturases appropriees pour modifier les niveaux d'acides gras polyinsatures dans des plantes a graines oleagineuses et de la levure oleagineuse
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
WO2005063231A2 (fr) 2003-12-31 2005-07-14 Igennus Limited Formulation contenant un acide carboxylique ou un ester de celui-ci
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
EP1591114A1 (fr) 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Utilisation de la metformine et de l'Orlistat pour le traitement ou la prévention de l'obésité
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
CN2724983Y (zh) 2004-05-17 2005-09-14 廖剑立 液压冲床复合油缸四导柱工作台
WO2005114190A2 (fr) 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Procedes pour identifier des marqueurs biologiques
TW200613009A (en) 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
WO2006017627A2 (fr) 2004-08-06 2006-02-16 Barry Sears Compositions dietetiques et procedes d'utilisation dans le traitement de l'insulinoresistance
US20090042979A1 (en) 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
BRPI0514189A (pt) 2004-08-06 2008-06-03 Transform Pharmaceuticals Inc composições farmacêuticas de estatina e métodos de tratamento relacionados
WO2006019140A1 (fr) 2004-08-18 2006-02-23 Mochida Pharmaceutical Co., Ltd. Préparation pour gelée alimentaire
ES2539969T3 (es) 2004-08-25 2015-07-07 Essentialis, Inc. Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US20070292523A1 (en) 2004-09-27 2007-12-20 Joey Moodley Dihydropyrimidine Formulations
WO2006085144A2 (fr) 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions contenant des niveaux eleves d'omega-3 et des niveaux faibles d'acides gras satures
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
MX2007006707A (es) 2004-12-06 2008-01-16 Reliant Pharmaceuticals Inc Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
US20070191467A1 (en) 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
CN101098690A (zh) 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US20090239927A1 (en) 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
US20060135610A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
EP1834639B8 (fr) 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Agent thérapeutique contre la toxicité des graisses
US20080200707A1 (en) 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
EP1853266B1 (fr) 2005-01-10 2011-10-12 Cortendo AB (publ) 2s,4r ketoconazole pour le traitement du diabete, du syndrome metabolique et d'autres conditions
US20060172012A1 (en) 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060189682A1 (en) 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
CA2598273A1 (fr) 2005-02-17 2006-08-24 Merck & Co., Inc. Methode de traitement de l'atherosclerose, de dyslipidemies et de troubles lies
US20100254951A1 (en) 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
BRPI0607569A2 (pt) 2005-03-08 2009-09-15 Reliant Pharmaceuticals Inc composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
TWI412361B (zh) 2005-07-08 2013-10-21 Mochida Pharm Co Ltd 預防心血管症候用組成物
JP5134916B2 (ja) 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
CA2615944A1 (fr) 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci
RU2290185C1 (ru) 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
CA2616806A1 (fr) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Traitement avec des inhibiteurs des canaux calciques a base de dihydropyridine et des acides gras omega-3 et produit combine contenant ceux-ci
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
EP1948168A4 (fr) 2005-10-28 2010-10-06 Numerate Inc Compositions et traitements destines a inhiber kinase et/ou hmg-coa reductase
US20070105793A1 (en) 2005-11-04 2007-05-10 Curt Hendrix Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
US20070104779A1 (en) 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
EP1946755B1 (fr) 2005-11-11 2017-03-15 Mochida Pharmaceutical Co., Ltd. Composition en gelee
WO2007058523A1 (fr) 2005-11-17 2007-05-24 N.V. Nutricia Composition comprenant de l'acide docosapentaenoique
BRPI0520669A2 (pt) 2005-11-21 2009-06-02 Teva Pharma dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
NZ569068A (en) 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
ES2366034T3 (es) 2005-12-23 2011-10-14 N.V. Nutricia Composición que comprende ácidos grasos poliinsaturados, proteínas, manganeso y/o molibdeno y nucleósidos/nucleótidos para el tratamiento de la demencia.
EP1973536A2 (fr) 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Traitement de foie graisseux
US20070202159A1 (en) 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
JP5069448B2 (ja) 2006-02-07 2012-11-07 持田製薬株式会社 脳卒中再発予防用組成物
ES2448424T3 (es) 2006-02-07 2014-03-13 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la recurrencia de accidente cerebrovascular
WO2007095174A2 (fr) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. derives d'acides biliaires en tant que ligands de FXR pour la prevention ou le traitement de maladies ou d'etats induits par FXR
CA2644154A1 (fr) * 2006-03-03 2007-09-13 Monsanto Technology Llc Moyens d'amelioration de la sante cardio-vasculaire
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007128801A1 (fr) 2006-05-08 2007-11-15 Novartis Ag Combinaison de composés organiques
ES2500063T3 (es) 2006-05-31 2014-09-29 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
US20070292501A1 (en) 2006-06-05 2007-12-20 Udell Ronald G Chewable soft gelatin capsules
NZ573719A (en) 2006-07-05 2011-08-26 Photonz Corp Ltd Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis
WO2008012329A2 (fr) 2006-07-28 2008-01-31 V. Mane Fils Gélules sans soudure contenant de grandes quantités d'acides gras polyinsaturés et un composant aromatisant
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
CN101553221A (zh) 2006-10-10 2009-10-07 瑞莱恩特医药品有限公司 用于降低APO-B水平的抑制素和ω-3脂肪酸
JP2010506920A (ja) 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
US20080306154A1 (en) * 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20080125490A1 (en) 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
JP5345402B2 (ja) 2007-01-17 2013-11-20 持田製薬株式会社 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
CA2676485A1 (fr) 2007-01-23 2008-07-31 Reddy Us Therapeutics, Inc. Procedes et compositions destines au traitement de la resistance a l'insuline, du diabete et d'une dyslipidemie associee au diabete
US20080185198A1 (en) 2007-02-02 2008-08-07 Steven Mark Jones Next generation hybrid III parallel/series hybrid system
AU2008215077B2 (en) 2007-02-15 2012-08-23 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
US20100055175A1 (en) 2007-03-06 2010-03-04 James Nugent Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
WO2008115529A1 (fr) 2007-03-20 2008-09-25 Reliant Pharmaceuticals, Inc. Compositions comprenant des acides gras omega-3 et des inhibiteurs de la cetp
WO2008145170A1 (fr) 2007-05-31 2008-12-04 Siemens Aktiengesellschaft Procédé pour configurer un système d'automatisation
US20080299187A1 (en) 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
EP2172225B1 (fr) 2007-06-29 2019-08-07 Takeda Pharmaceutical Company Limited Capsule sans soudure
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
US8361534B2 (en) 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
EP2242382B1 (fr) 2007-12-20 2016-11-16 Abbott Laboratories Poudre nutritionnelle stable
KR20100111292A (ko) 2008-01-10 2010-10-14 다케다 야쿠힌 고교 가부시키가이샤 캡슐 제제
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
EP2291499B1 (fr) 2008-05-15 2020-02-12 Basf As Procédé se rapportant à l'huile de krill
JPWO2009142242A1 (ja) * 2008-05-20 2011-09-29 持田製薬株式会社 ハイリスク患者の心血管イベント予防用組成物
JPWO2009151116A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2009151125A1 (fr) 2008-06-13 2009-12-17 持田製薬株式会社 Diagnostic et traitement d’un trouble hépatique
WO2009154230A1 (fr) 2008-06-17 2009-12-23 持田製薬株式会社 Agent de prévention/amélioration ou de traitement de la stéatose hépatique non alcoolique
WO2010004982A1 (fr) 2008-07-07 2010-01-14 持田製薬株式会社 Agent améliorant ou thérapeutique pour une dyslipidémie
JP5676446B2 (ja) 2008-07-30 2015-02-25 アクラレント インコーポレイテッド 副鼻洞口ファインダ
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
CA2738985A1 (fr) 2008-09-30 2010-04-08 Mochida Pharmaceutical Co., Ltd. Agent therapeutique pour l'hepatite c
WO2010040012A1 (fr) 2008-10-01 2010-04-08 Martek Biosciences Corporation Compositions et procédés de réduction de taux de triglycérides
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
EP2405921A4 (fr) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc Compositions et procédés d'inactivation de l'expression de l'apolipoprotéine c-iii
SG10201610916SA (en) 2009-02-10 2017-02-27 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2010117951A1 (fr) 2009-04-06 2010-10-14 The Regents Of The University Of California Inhibiteurs d'époxyde hydrolase soluble pour inhiber ou prévenir des bouffées vasomotrices induites par la niacine
NZ595852A (en) 2009-04-29 2014-07-25 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
WO2010127099A2 (fr) * 2009-04-29 2010-11-04 Amarin Corporation Plc Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2010134614A1 (fr) 2009-05-22 2010-11-25 持田製薬株式会社 COMPOSITION AUTO-ÉMULSIFIANTE D'ACIDE GRAS ω3
SMT202100223T1 (it) 2009-06-15 2021-05-07 Amarin Pharmaceuticals Ie Ltd Composizioni e metodi per abbassare i trigliceridi senza aumentare i livelli di ldl-c in un soggetto in terapia concomitante con statine
RU2402326C1 (ru) 2009-06-22 2010-10-27 Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) Способ коррекции инсулинорезистентности при метаболическом синдроме
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
BR112012004677A2 (pt) 2009-09-01 2020-11-03 Catabasis Pharmaceuticals, Inc. conjugados de ácido graxo niacina e seus usos
RU2012116079A (ru) 2009-09-23 2013-10-27 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
EP2490026A4 (fr) 2009-10-16 2013-08-21 Mochida Pharm Co Ltd Marqueur associé à la stéatohépatite non alcoolique
SG182414A1 (en) 2010-01-08 2012-08-30 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses
WO2011087981A2 (fr) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Bénéfices cliniques de l'acide eicosapentaénoïque chez des humains
JP6327497B2 (ja) 2010-03-04 2018-05-23 アマリン ファーマシューティカルズ アイルランド リミテッド 心血管疾患を処置及び／又は予防するための組成物及び方法
US8846321B2 (en) 2010-03-12 2014-09-30 President And Fellows Of Harvard College Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US20130156892A1 (en) 2010-05-05 2013-06-20 St. Giles Foods Limited Edible compositions and methods of manufacturing edible compositons
JP5829607B2 (ja) 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
AR082930A1 (es) 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
EP2630501A4 (fr) 2010-10-20 2014-04-16 Glycomark Inc Identification améliorée d'un état prédiabétique en utilisant comme marqueurs la glycémie moyenne et le 1,5-anhydroglucitol en combinaison
CN103338762B (zh) 2010-11-09 2015-03-25 持田制药株式会社 血糖值上升抑制剂
EP2646013A4 (fr) 2010-11-29 2014-03-26 Amarin Pharma Inc Composition à faible éructation et méthodes de traitement et/ou de prévention de maladie cardiovasculaire chez un sujet présentant une allergie/hypersensibilité aux poissons
KR101310710B1 (ko) 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2012149495A1 (fr) 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation de l'expression de l'apolipoprotéine ciii (apociii)
US20130095179A1 (en) 2011-09-15 2013-04-18 Omthera Pharmaceuticals, Inc. Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2792746A4 (fr) 2011-12-12 2015-09-16 Nat Cerebral & Cardiovascular Ct Oligonucléotide anisi qu'agent thérapeutique pour l'hyperlipidémie contenant cet oligonucléotide en tant que principe actif
US9827219B2 (en) 2012-01-06 2017-11-28 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
IL249821B (en) 2012-03-30 2019-04-30 Sancilio & Company Inc Omega-3 fatty acid ester compositions
RU2645075C2 (ru) 2012-05-07 2018-02-15 Омтера Фармасьютикалс, Инк. Композиции статинов и омега-3 жирных кислот
KR20200074259A (ko) 2012-05-15 2020-06-24 모치다 세이야쿠 가부시키가이샤 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
JP6473414B2 (ja) 2012-05-30 2019-02-20 クラリアント・ファイナンス・（ビーブイアイ）・リミテッド 向上した泡品質及びより高い粘度を有する、アミノ酸系界面活性剤、ベタイン類及びｎ−メチル−ｎ−アシルグルカミンを含む組成物
US20130324607A1 (en) 2012-06-05 2013-12-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypercholesterolemia
US20140080850A1 (en) 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
WO2013192109A1 (fr) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
US20140004183A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US20150157593A1 (en) 2012-06-29 2015-06-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
RU2020125675A (ru) 2012-06-29 2020-09-16 Амарин Фармасьютикалз Айрлэнд Лимитед Способы лечения педиатрического метаболического синдрома
US20140005265A1 (en) 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
NZ703267A (en) 2012-06-29 2017-01-27 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014050692A1 (fr) 2012-09-28 2014-04-03 持田製薬株式会社 Composition pour réduire de nouvelles apparitions de diabète
EP2719382A1 (fr) 2012-10-12 2014-04-16 Mochida Pharmaceutical Co., Ltd. Éthyl eicosapentanoate et compositions pharmaceutiques comprenant de l'éthyle eicosapentanoate comme ingrédient actif pour une utilisation dans le traitement d'une stéatohépatite non alcoolique
WO2014057522A1 (fr) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions et procédés de traitement de la stéatohépatite non alcoolique
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140213648A1 (en) 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US20140221676A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US20140221358A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US20140221452A1 (en) 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US20140242216A1 (en) 2013-02-24 2014-08-28 Mead Johnson Nutrition Company Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140249214A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of warfarin and ethyl eicosapentaenoate
US20140249225A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
US20140249220A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
US20140249200A1 (en) 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US9661874B2 (en) 2013-03-11 2017-05-30 Mead Johnson Nutrition Company Nutritional compositions containing structured fat globules and uses thereof
US20140255537A1 (en) 2013-03-11 2014-09-11 Mead Johnson Nutrition Company Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
US20140275252A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Methods of treating traumatic brain injury
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271907A1 (en) 2013-03-14 2014-09-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
JP6442412B2 (ja) 2013-03-15 2018-12-19 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014179325A1 (fr) 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Formulations d'acides gras oméga-3 destinées à être utilisées comme traitement pharmaceutique
US20140357717A1 (en) 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
EP3735963B1 (fr) 2013-07-18 2023-09-13 Mochida Pharmaceutical Co., Ltd. Composition auto-émulsifiante d'acides gras oméga-3
KR102275447B1 (ko) 2013-07-18 2021-07-08 모치다 세이야쿠 가부시키가이샤 ω3 지방산의 자기 유화 조성물
US20150045431A1 (en) 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
US20150051282A1 (en) 2013-08-14 2015-02-19 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US20150073050A1 (en) 2013-09-09 2015-03-12 Amarin Pharmaceuticals Ireland Limited Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (fr) 2013-10-31 2015-05-07 Amarin Pharmaceuticals Ireland Limited Méthodes de traitement de l'hypertriglycéridémie
SG11201608077PA (en) 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP2017531306A (ja) 2014-08-01 2017-10-19 ウェスタン・ミシガン・ユニバーシティ・リサーチ・ファウンデイションＷｅｓｔｅｒｎ Ｍｉｃｈｉｇａｎ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 自立式電子デバイス
CN107405326B (zh) 2015-01-21 2021-06-15 持田制药株式会社 ω3脂肪酸的自乳化组合物
SG11201705938TA (en) 2015-01-21 2017-08-30 Mochida Pharm Co Ltd SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
WO2016140949A1 (fr) 2015-03-02 2016-09-09 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de la modification oxydative des acides gras polyinsaturés membranaires
US20170151202A1 (en) 2015-09-09 2017-06-01 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
DK3275438T3 (da) 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US20190054058A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods of Treating or Preventing Bone Loss
US20190054054A1 (en) 2017-08-15 2019-02-21 Amarin Pharmaceuticals Ireland Limited Methods reducing or preventing oxidation of high density lipoprotein (HDL)
US20190209506A1 (en) 2018-01-09 2019-07-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190275057A1 (en) 2018-03-06 2019-09-12 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
TN2021000028A1 (en) 2018-08-17 2022-10-03 Amarin Pharmaceuticals Ie Ltd Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
PL4056176T3 (pl) 2018-09-24 2024-08-26 Amarin Pharmaceuticals Ireland Limited Sposoby zmniejszania ryzyka zdarzeń krążeniowo-naczyniowych u osobnika
BR112021005813A2 (pt) 2018-09-26 2021-06-29 Amarin Pharmaceuticals Ireland Limited composições e métodos para tratar ou prevenir doenças e/ou distúrbios causados pela exposição à poluição do ar

Also Published As

Publication number Publication date
BR112014032905A2 (pt) 2017-06-27
IL275396B1 (en) 2024-07-01
NZ743706A (en) 2019-08-30
MA50258B2 (fr) 2024-05-31
US20200078329A1 (en) 2020-03-12
US20200113864A1 (en) 2020-04-16
US20190076389A1 (en) 2019-03-14
EP3363433A1 (fr) 2018-08-22
AU2018204499A1 (en) 2018-07-12
US10278938B2 (en) 2019-05-07
US20180289658A1 (en) 2018-10-11
EP4342546A2 (fr) 2024-03-27
LT3815684T (lt) 2024-11-25
EA201500069A1 (ru) 2015-04-30
IL236376A0 (en) 2015-02-26
CU20140151A7 (es) 2016-03-31
IL275396A (en) 2020-07-30
MX2020008890A (es) 2022-08-15
EP3363433B1 (fr) 2020-12-09
ES2846176T3 (es) 2021-07-28
WO2014005013A2 (fr) 2014-01-03
PE20150770A1 (es) 2015-05-16
US20170258755A1 (en) 2017-09-14
HUE053111T2 (hu) 2021-06-28
IL313596A (en) 2024-08-01
PT3363433T (pt) 2021-02-15
US9693985B2 (en) 2017-07-04
MX2020002907A (es) 2022-05-30
AU2020294210B2 (en) 2024-06-13
US10278936B2 (en) 2019-05-07
MX392694B (es) 2025-03-24
US20190083445A1 (en) 2019-03-21
NZ743714A (en) 2019-08-30
CL2014003534A1 (es) 2015-06-12
US20180289657A1 (en) 2018-10-11
JP2015522029A (ja) 2015-08-03
UA118015C2 (uk) 2018-11-12
PH12014502849A1 (en) 2015-02-23
US9603826B2 (en) 2017-03-28
DOP2014000301A (es) 2015-06-30
US20150157592A1 (en) 2015-06-11
US10278939B2 (en) 2019-05-07
US20190076388A1 (en) 2019-03-14
LT3363433T (lt) 2021-02-25
US10894028B2 (en) 2021-01-19
US10555925B1 (en) 2020-02-11
US10278935B2 (en) 2019-05-07
HRP20210309T1 (hr) 2021-04-02
CR20140591A (es) 2015-05-06
AU2020294210A1 (en) 2021-01-28
MX2020013933A (es) 2022-11-23
DK3815684T3 (da) 2024-10-21
US9918955B2 (en) 2018-03-20
NI201400155A (es) 2016-10-11
MA50258A1 (fr) 2023-07-31
IL236376B (en) 2020-09-30
US9623001B2 (en) 2017-04-18
US20170035722A1 (en) 2017-02-09
US10016386B2 (en) 2018-07-10
JP2018184463A (ja) 2018-11-22
US20170258753A1 (en) 2017-09-14
EA201890380A1 (ru) 2018-11-30
RS65970B1 (sr) 2024-10-31
CN111840268A (zh) 2020-10-30
MX2015000138A (es) 2015-09-07
CN111840269A (zh) 2020-10-30
US20200038358A1 (en) 2020-02-06
US10383840B2 (en) 2019-08-20
US20190192472A1 (en) 2019-06-27
MX394764B (es) 2025-03-24
US20200163925A1 (en) 2020-05-28
US20190343788A1 (en) 2019-11-14
WO2014005013A3 (fr) 2014-02-20
SI3363433T1 (sl) 2021-05-31
MX378496B (es) 2025-03-11
FI3815684T3 (fi) 2024-09-30
ES2993235T3 (en) 2024-12-26
IL275396B2 (en) 2024-11-01
MX394763B (es) 2025-03-24
US9610272B2 (en) 2017-04-04
KR20150036252A (ko) 2015-04-07
CO7190236A2 (es) 2015-02-19
EA039108B1 (ru) 2021-12-06
US9693984B2 (en) 2017-07-04
RS61557B1 (sr) 2021-04-29
EP4338805A3 (fr) 2024-05-22
SG11201408769QA (en) 2015-01-29
HK1204271A1 (en) 2015-11-13
EP4338805A2 (fr) 2024-03-20
US10278937B2 (en) 2019-05-07
SMT202100220T1 (it) 2021-05-07
EP2866801A4 (fr) 2016-02-10
GEP201706768B (en) 2017-11-10
PT3815684T (pt) 2024-09-24
BR112014032905B1 (pt) 2022-02-22
US20170143656A1 (en) 2017-05-25
US20170056361A1 (en) 2017-03-02
US10568861B1 (en) 2020-02-25
SG10201703867RA (en) 2017-06-29
HUE069516T2 (hu) 2025-03-28
EP2866801A2 (fr) 2015-05-06
EP4342546A3 (fr) 2024-05-22
SI3815684T1 (sl) 2025-01-31
CA3067008C (fr) 2021-10-26
US20170258754A1 (en) 2017-09-14
MX2022010507A (es) 2022-09-21
US20230338323A1 (en) 2023-10-26
CA3067012A1 (fr) 2014-01-03
AU2013282394A1 (en) 2015-01-22
ECSP15002815A (es) 2017-03-31
MY187464A (en) 2021-09-23
SG10201913647QA (en) 2020-03-30
CA3067012C (fr) 2021-10-05
US20200069632A1 (en) 2020-03-05
US10792270B2 (en) 2020-10-06
US20200038359A1 (en) 2020-02-06
US20170143658A1 (en) 2017-05-25
TN2014000540A1 (en) 2016-03-30
US20190321323A1 (en) 2019-10-24
EP3815684B1 (fr) 2024-09-04
CA3067008A1 (fr) 2014-01-03
US20180153846A1 (en) 2018-06-07
US9918954B2 (en) 2018-03-20
US10555924B2 (en) 2020-02-11
PL3815684T3 (pl) 2025-01-20
US20180289659A1 (en) 2018-10-11
MX2020013922A (es) 2022-08-15
NZ727849A (en) 2018-06-29
PL3363433T3 (pl) 2021-06-14
CY1123749T1 (el) 2022-05-27
EA029988B1 (ru) 2018-06-29
SG10201913645RA (en) 2020-03-30
NZ737380A (en) 2019-05-31
CN104582698A (zh) 2015-04-29
DK3363433T3 (da) 2021-03-08
NZ703267A (en) 2017-01-27
SMT202400504T1 (it) 2025-01-14
CA2877514A1 (fr) 2014-01-03
US20170119723A1 (en) 2017-05-04
AU2013282394B2 (en) 2018-04-26
EP3815684A1 (fr) 2021-05-05
AU2018204499B2 (en) 2020-09-24
SG10201913646PA (en) 2020-03-30
UA128280C2 (uk) 2024-05-29
US10576054B1 (en) 2020-03-03
CN111166736A (zh) 2020-05-19
US9693986B2 (en) 2017-07-04
JP2020073492A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
HK1204271A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HK1211475A1 (en) Combination therapy
ZA201406969B (en) Combination therapy with an anti-hyaluronan agent and a tumor-targreted taxane
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1198116A1 (en) A chair and a method of using the chair
HK1208318A1 (en) A chair and supports
GB201217439D0 (en) Combination therapy
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
IL238174A0 (en) Combined treatment with Valasertiv
GB201102231D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102208D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy